Short Term Price Target on Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) stock is expected to deviate a maximum of $15.96 from the average target price of $94.58 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $116 and the most muted being $55.

Shares of Eli Lilly and Company rose by 6.51% in the last five trading days and 5.08% for the last 4 weeks. Eli Lilly and Company is up 7.98% in the last 3-month period. Year-to-Date the stock performance stands at -5.26%.

Eli Lilly and Company (NYSE:LLY) has an average broker rating of 1.92, which is interpreted as a Buy, as rated by 13 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Eli Lilly and Company (NYSE:LLY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $78.20 and $77.46 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $78.81. The buying momentum continued till the end and the stock did not give up its gains. It closed at $78.75, notching a gain of 0.77% for the day. The total traded volume was 4,017,154 . The stock had closed at $78.15 on the previous day.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.